Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
about
Inhibitor of MYC identified in a Kröhnke pyridine libraryBiological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel constructDisulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicinesCremophor-induced lupus erythematosus-like reaction with taxol administration: a case report and review of the literature.Synergistic complex from plants Solanaceae exhibits cytotoxicity for the human hepatocellular carcinoma cell line HepG2Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical interventionA Hyperresponsive HPA Axis May Confer Resilience Against Persistent Paclitaxel-Induced Mechanical HypersensitivityRecovery sleep does not mitigate the effects of prior sleep loss on paclitaxel-induced mechanical hypersensitivity in Sprague-Dawley rats.Paclitaxel drug delivery systems.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cellsIn vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.Immunological effects of taxol and adryamicin in breast cancer patients.Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.
P2860
Q28656132-B8CC19A9-E883-46EB-8082-40A3F131ADAFQ34038519-24B637DA-EB11-46AB-BD03-5D4C3BB8DBE8Q35100603-2ECD673F-4AFF-45B1-90B9-EBD9B79076DAQ35574188-BE16DCB5-42A3-4F11-894E-78A08E11C921Q36166833-296EF6D2-8099-49ED-9CD7-C3471FD4E489Q36648388-061C7068-EE30-4175-AD35-1996A4551207Q37526640-E8AAA2AE-0B3B-499D-A7D6-1C4CE0C7D1B3Q37536111-DC145070-79FA-4849-8C2D-C834B005AF67Q38071668-FECC47C5-5099-413A-AA6F-80B7B7C35846Q38132699-E5FB3F41-5D8C-49F6-961E-B97E1EA2FEB3Q39048858-A37F38BC-E2A1-4788-81F9-346385BF86E2Q39833283-714A1B1D-A33A-497A-9745-751D026C9F4FQ43745676-A7A25EAE-DAFF-4E4D-B592-9987C6A02230Q45661616-FD3C5C17-26DC-41C5-B766-C6A5C400787AQ45917628-9E862212-8C26-43D0-9AA6-89808B30AABAQ48025703-FEB0C0AA-9FDE-43DF-8088-46B8898CC283
P2860
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@ast
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@en
type
label
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@ast
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@en
prefLabel
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@ast
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@en
P2860
P1476
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
@en
P2093
Charity D Scripture
William D Figg
P2860
P304
P356
10.2147/TCRM.1.2.107.62910
P577
2005-06-01T00:00:00Z